Skip to main content

Name
John Fisher

Thu, 07/18/2013 - 04:51

Stephen, great blog. The deep brain story and its translation to superior treatment for Parkinson’s diseases is one from the emerging field of “electroceuticals” (1,2). Drs. Levy, Reid and Pari are part of a growing field “Correcting such disorders with treatment in their own electrical language…”(1). A recent commentary in Nature, by Famm (Head of Bioelectronics research at Glaxo Smith Kline, GSK) trumpeted the remarkable potential for electroceuticals to impact human health, which generated 12,000 views since April. The field weaves together the skillsets of engineers, neurosurgeons, clinical investigators, neuroscientists, pain biologists and other PhD scientists into an apparently coherent pattern. Interestingly, GSK has announced plans to fund 20 projects related to “bioelectronic medicine’ (2), as well as a global research leaders forum to identify a “ key hurdle” followed by a potential $1M international prize for solutions (1). Electroceuticals are a Darwinian leap for big pharma, from compounds to electrons. 1. Famm et al “Drug Discovery: a jump start for eletroceuticals. Nature 496, 159–161 (11 April 2013) doi:10.1038/496159a (http://www.nature.com/nature/journal/v496/n7444/full/496159a.html 2. Sinha, G. Charged by GSK investment, battery of electroceuticals advance. Nature Medicine 19, 654 (2013) doi:10.1038/nm0613-654 http://www.nature.com/nm/journal/v19/n6/full/nm0613-654.html

Name
John Fisher
The content of this field is kept private and will not be shown publicly.

Plain text

  • No HTML tags allowed.
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.